Rohto Pharmaceutical Co., Ltd. — Cyborg Score 6/10

Solid
Household & Personal Products / Over-The-Counter Pharmaceuticals

Strategic Profile

Rohto is a leading Japanese pharmaceutical company based in Osaka, Japan that operates primarily in the healthcare and wellness industry, specializing in over-the-counter drugs, skin care products, and functional foods. The company operates beauty counters that provide beauty and health services, manufactures and sells diagnostic reagents, and provides investment management services and contract development and manufacturing services.

Cyborg Score Rationale

Rohto is currently running a trailing net profit margin of 10.3%, compared with 10.0% a year earlier, while revenue growth is forecast at about 4.5% per year and earnings growth at around 4% per year, both described as slower than the broader Japan market averages. The company maintains stable profitability and market position but faces moderating growth expectations.

Top Insights

  • The last year delivered an exceptional 32% gain to the company's bottom line, with EPS growth of 54% over the last three years.
  • Trading at 47% below our estimate of its fair value according to some valuation models.
  • Estimates from ten analysts covering the company suggest earnings should grow by 1.5% per year over the next three years.
  • Undervalued with solid track record and pays a dividend.

Named Competitors

  • OTC Pharmaceuticals — Japanese OTC drug and health product competitor
  • Cosmetics & Personal Care — Global consumer health and beauty products
  • Premium Beauty Products — International cosmetics and skin care leader

Recent Developments

  • (Q3 2026) Rohto reported clean results with total revenue of ¥88,814 million and basic EPS of ¥47.03, while net income came in at ¥10,627 million.
  • (November 2025) Interim results met expectations with margins remaining stable at 10.3%
  • (2025) Continued focus on organic growth and profitability across OTC drug and cosmetics portfolios

Open the full interactive Rohto Pharmaceutical Co., Ltd. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →